Pharmasset proposes follow-on

Pharmasset Inc. (NASDAQ:VRUS) proposed late Wednesday to raise $30 million in a follow-on underwritten by Leerink. Pharmasset has two compounds in Phase II testing for HCV: RG7128, a prodrug of PSI-61...